Targeting ABCA1 via Extracellular Vesicle‐Encapsulated Staurosporine as a Therapeutic Strategy to Enhance Radiosensitivity
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Qi Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical …. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter 1, Staurosporine, Extracellular Vesicles, Radiation Tolerance. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Cancer stem cells (CSCs) are essential for tumor initiation, recurrence, metastasis, and resistance. However, targeting CSCs as a therapeutic approach remains challenging. Here, a stemness signature based on 22‐gene is developed to predict prognosis in esophageal squamous cell carcinoma (ESCC). Staurosporine (STS) is identified as a radioresistance suppressor by high‐throughput screening of a library of 2131 natural compounds, leading to dramatically improved radiotherapy efficacy in subcutaneous tumor models. Mechanistically, STS inhibits cell proliferation through the mTOR/AKT signaling pathway and suppressed stemness by targeting ATP‐binding cassette A1 (ABCA1), which is transcriptionally regulated by liver X receptor alpha (LXRα). STS can selectively bind to the nucleotide‐binding domain (NBD) of ABCA1 and compete for ATP, blocking ABCA1‐mediated drug efflux and facilitating intracellular accumulation of STS. Considering the cytotoxicity of STS, an extracellular vesicle‐encapsulated STS system (EV‐STS) is established for effective STS delivery. EV‐STS shows remarkable tumor growth inhibition, even at half the dose of STS, with superior safety and efficacy. These findings indicate that ABCA1 may serve as a predictor of response to neoadjuvant chemotherapy and/or radiotherapy in ESCC patients. EV‐STS has shown improved antitumor efficacy and low systemic toxicity, offering a promising therapeutic approach for ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
- Biobank, Cancer Research Center, Shandong Cancer Hospital, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
ORCID-Profile: Zhihua Liu
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- CAMS Innovation Fund for Medical Sciences
- National Key Research and Development Program of China
Zitieren
APA
Yang, Q., Gao, W., Li, X., Li, X., Zhou, X., Li, W., Zhou, C., Luo, A., & Liu, Z. (2024). Targeting ABCA1 via Extracellular Vesicle‐Encapsulated Staurosporine as a Therapeutic Strategy to Enhance Radiosensitivity. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400381
Vancouver
Yang Q, Gao W, Li X, Li X, Zhou X, Li W, et al. Targeting ABCA1 via Extracellular Vesicle‐Encapsulated Staurosporine as a Therapeutic Strategy to Enhance Radiosensitivity. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400381
BibTeX
@article{Yang2024,
author = {Yang, Qi and Gao, Wenyan and Li, Xinyue and Li, Xin and Zhou, Xuantong and Li, Wenxin and Zhou, Changchun and Luo, Aiping and Liu, Zhihua},
title = {Targeting ABCA1 via Extracellular Vesicle‐Encapsulated Staurosporine as a Therapeutic Strategy to Enhance Radiosensitivity},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400381}
}
EUVIMED